On September 18, 2026 the Depo-Provera court will hold a case management conference and then hear the parties’ general causation and Rule 702 motions — the argument over whether the expert evidence that injectable medroxyprogesterone acetate can cause meningioma is admissible at all. The same hearing will address three newly substituted pilot cases, and the question teed up in them is not causation. It is the statute of limitations. The original pilot plaintiffs turned out to be eligible for the settlement, so the defendants moved to substitute three others and to put a time-based defense first, on the theory that the answer could be broadly applicable. The plaintiffs’ lawyers consented.
What is being argued
Two things, in sequence. The parties completed general causation discovery and had fully briefed their general causation summary judgment and related Rule 702 motions by June 5, 2026. Rule 702 is the federal rule governing expert testimony; a ruling under it decides whether a jury ever hears an expert opinion, which in a case like this decides whether the case can be tried at all. A separate preemption question was argued earlier and is awaiting decision.
The hearing follows the case management conference set for 9:00 a.m. Central on Friday, September 18, 2026, with the parties’ joint agenda letter due to the MDL court and to the New York, Delaware and California state courts by noon on September 14.
Why the rulings matter less than they would have
Before the settlement, these motions were the whole ballgame. They are narrower now. The court has said it will rule on preemption and general causation for the purpose of cases that are ineligible for the settlement program or whose plaintiffs opt out, and that those rulings will not affect plaintiffs who are eligible and elect to participate. Eligibility is defined inside the private settlement agreement and does not move with the court’s decisions.
So the same hearing carries very different weight depending on which side of the eligibility line a person is on. For those inside the program, it is essentially litigation news. For those outside it, it is the question of whether there is a case.
Three new pilot cases, and a defense that goes first
The court had set an initial bellwether trial for December 7, 2026. When the settlement was announced the court vacated the pilot schedule and canceled that trial, because the original pilot plaintiffs were themselves eligible to participate. The defendants then moved to substitute three replacements:
- Christina Yeager v. Pfizer, Inc., et al., No. 3:26-cv-3733
- Vivian Davis v. Pfizer, Inc., et al., No. 3:26-cv-3826
- Katherine Allison Ponder v. Pfizer, Inc., et al., No. 3:26-cv-3896
The defense also asked to run those cases on an expedited schedule focused on the statute of limitations, arguing the issue could be broadly applicable. At the July conference each plaintiff’s attorney consented to the substitution, adopted the previously filed briefing and said they were ready to go forward on September 18. Counsel for Ms. Davis asked for a slight delay to accommodate her recovery from recent medical treatment, proposing written discovery first and no deposition before September 12, 2026; the court found that reasonable. The court agreed that teeing up the limitations question first was the most efficient way to proceed.
A time-based defense does not argue that nothing happened. It argues that it is too late to say so in court.
What this means for someone deciding whether to call
It means the calendar is doing as much work in this litigation as the science, and it is doing it first. A claim can be outside the settlement program because of the date an action was commenced, and a pilot case can be decided on whether a filing came in time rather than on what the medication did. Deadlines to bring a claim vary by state and by circumstance, and the useful step is not to work them out from a news article.
Meanwhile the docket itself keeps moving. As of late July there were 6,289 member actions in the federal MDL, with separate state court proceedings including 410 cases in Delaware, 129 in New York and 118 in California, where preemption has been briefed and bellwether cases selected. Rule 702 arguments were heard in the Delaware proceeding on June 25, 2026 and remain under review.
This article is general information about how these cases work. It is not legal advice, it does not create an attorney-client relationship, and no two claims are alike. If something here sounds like your situation, the useful next step is a conversation about the facts.
